Baseline clinical characteristics of all patients with
| Total (N=96) | Parameter | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, years | 15–39 (AYA) | 40–59 (adult) | ≥60 (elderly) | |||||||||||||||
| N (%) | 53 (55.2) | 38 (39.6) | 5 (5.2) | |||||||||||||||
| Median (range) | 37.5 (14–59) | |||||||||||||||||
| Sex | Male | Female | ||||||||||||||||
| N (%) | 42 (43.8) | 54 (56.3) | ||||||||||||||||
| Ethnicity | Malay | Chinese | Indian | Others | ||||||||||||||
| N (%) | 48 (50.0) | 37 (38.5) | 9 (9.4) | 2 (2.1) | ||||||||||||||
| WCC, at diagnosis | >30×109/L | <30×109/L | ||||||||||||||||
| N (%) | 51 (53.1) | 45 (46.9) | ||||||||||||||||
| Median (range), ×109/L | 36 (2–500) | |||||||||||||||||
| MRD status | TP1 | TP2 | TP3 | |||||||||||||||
| ≥0.1% | <0.1% | ≥0.1% | <0.1% | ≥0.1% | <0.1% | |||||||||||||
| N | 31 | 25 | 25 | 40 | 13 | 36 | ||||||||||||
| Missing | 40 | 31 | 47 | |||||||||||||||
| Treatment modalities | GMALL/BFM | Hyper-CVAD | TKIs | |||||||||||||||
| Yes (2012–2018) | No (2006–2011) | |||||||||||||||||
| N (%) | 49 (51) | 47 (49) | 62 (64.6) | 34 (35.4) | ||||||||||||||
| Treatment response | Remission post-induction | Overall remission | Relapse | Refractory | Induction death | |||||||||||||
| N (%) | 80 (83.3) | 38 (41.3) | 34 (37.0) | 10 (10.9) | 4 (4.3) | |||||||||||||
| Transplant | Yes | No | ||||||||||||||||
| N (%) | 38 (39.6) (33-Allogeneic; 5-Autologous) |
58 (60.4) | ||||||||||||||||
Values are presented as mean, median (range), or number (%).
Abbreviations: ALL, acute lymphoblastic leukemia; AYA, adolescent and young adult; MRD, measurable residual disease; TKI, tyrosine kinase inhibitor; TP1, timepoint 1; TP2, timepoint 2; TP3, timepoint 3; WCC, white cell count.
Blood Res 2021;56:175~183 https://doi.org/10.5045/br.2021.2021045
© Blood Research
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd